CL2012001300A1 - Proceso de preparación de un compuesto de fórmula (i) en forma de sal iónica, que comprende las etapas de i) hidrogenar un compuesto de fórmula (ii) usando un catalizador metálico con hidrógeno y ii) filtrar el catalizador seguido de tratamiento con una solución ácida o gas. - Google Patents

Proceso de preparación de un compuesto de fórmula (i) en forma de sal iónica, que comprende las etapas de i) hidrogenar un compuesto de fórmula (ii) usando un catalizador metálico con hidrógeno y ii) filtrar el catalizador seguido de tratamiento con una solución ácida o gas.

Info

Publication number
CL2012001300A1
CL2012001300A1 CL2012001300A CL2012001300A CL2012001300A1 CL 2012001300 A1 CL2012001300 A1 CL 2012001300A1 CL 2012001300 A CL2012001300 A CL 2012001300A CL 2012001300 A CL2012001300 A CL 2012001300A CL 2012001300 A1 CL2012001300 A1 CL 2012001300A1
Authority
CL
Chile
Prior art keywords
compound
formula
catalyst
hydrogenating
filtering
Prior art date
Application number
CL2012001300A
Other languages
English (en)
Spanish (es)
Inventor
Hossein Razavi
Jonathan Timothy Reeves
Sonia Rodriguez
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2012001300A1 publication Critical patent/CL2012001300A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/70Sulfur atoms
    • C07D213/71Sulfur atoms to which a second hetero atom is attached
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/38Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
    • B01J23/40Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals of the platinum group metals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Materials Engineering (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Steroid Compounds (AREA)
CL2012001300A 2009-12-08 2012-05-18 Proceso de preparación de un compuesto de fórmula (i) en forma de sal iónica, que comprende las etapas de i) hidrogenar un compuesto de fórmula (ii) usando un catalizador metálico con hidrógeno y ii) filtrar el catalizador seguido de tratamiento con una solución ácida o gas. CL2012001300A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26753809P 2009-12-08 2009-12-08

Publications (1)

Publication Number Publication Date
CL2012001300A1 true CL2012001300A1 (es) 2012-09-07

Family

ID=43416915

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012001300A CL2012001300A1 (es) 2009-12-08 2012-05-18 Proceso de preparación de un compuesto de fórmula (i) en forma de sal iónica, que comprende las etapas de i) hidrogenar un compuesto de fórmula (ii) usando un catalizador metálico con hidrógeno y ii) filtrar el catalizador seguido de tratamiento con una solución ácida o gas.

Country Status (17)

Country Link
US (1) US20110137042A1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
EP (1) EP2509952A1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
JP (1) JP2013512954A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
KR (1) KR20120101667A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
CN (1) CN102596908A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
AR (1) AR079324A1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
AU (1) AU2010328480A1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
BR (1) BR112012013582A2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
CA (1) CA2782384A1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
CL (1) CL2012001300A1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
EA (1) EA201200820A1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
IL (1) IL219274A0 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
IN (1) IN2012DN05081A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
MX (1) MX2012006524A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
PH (1) PH12012501153A1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
TW (1) TW201144282A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
WO (1) WO2011071730A1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008327B2 (en) 2008-04-29 2011-08-30 Boehringer Ingelheim International Gmbh Indazole compounds as CCR1 receptor antagonists
CA2722811C (en) 2008-05-06 2016-07-05 Boehringer Ingelheim International Gmbh Pyrazole compounds as ccr1 antagonists
US7879873B2 (en) 2008-09-26 2011-02-01 Boehringer Ingelheim International Gmbh Azaindazole compounds as CCR1 receptor antagonists
EP2491028B1 (en) 2009-10-21 2013-12-11 Boehringer Ingelheim International GmbH Indazole and pyrazolopyridine compounds as ccr1 receptor antagonists
JP5542214B2 (ja) 2009-10-27 2014-07-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ccr1受容体アンタゴニストとしての複素環化合物
WO2011137109A1 (en) 2010-04-30 2011-11-03 Boehringer Ingelheim International Gmbh Azaindazole amide compounds as ccr1 receptor antagonists
WO2012087782A1 (en) 2010-12-23 2012-06-28 Boehringer Ingelheim International Gmbh Pyrazolopiperidine compounds as ccr1 receptor antagonists

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242931A (en) * 1988-06-09 1993-09-07 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds as TXA2 antagonists
CA1338625C (en) * 1988-06-09 1996-10-01 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds
US5750542A (en) * 1993-09-28 1998-05-12 Pfizer Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors
US5612360A (en) * 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
EP0606489A4 (en) * 1992-07-03 1995-01-25 Kumiai Chemical Industry Co CONDENSED HETEROCYCLIC DERIVATIVES AND WEED KILLERS.
GB9304919D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
AU674240B2 (en) * 1993-06-25 1996-12-12 Ihara Chemical Industry Co. Ltd. Indazolesulfonylurea derivative, use thereof, and intermediate for production thereof
AU699281B2 (en) * 1994-12-06 1998-11-26 Merck Sharp & Dohme Limited Azetidine, pyrrolidine and piperidine derivatives as 5HT1 receptor agonists
GB9519563D0 (en) * 1995-09-26 1995-11-29 Merck Sharp & Dohme Therapeutic agents
GB9523583D0 (en) * 1995-11-17 1996-01-17 Merck Sharp & Dohme Therapeutic agents
US5760028A (en) * 1995-12-22 1998-06-02 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
GB9615449D0 (en) * 1996-07-23 1996-09-04 Merck Sharp & Dohme Therapeutic agents
KR20010031783A (ko) * 1997-11-04 2001-04-16 데이비드 존 우드 Pde4 억제제 중 인다졸에 의한 카테콜의 생등입체성치환을 기재로 하는 치료상 활성인 화합물
US6331640B1 (en) * 1998-10-13 2001-12-18 Hoffmann-La Roche Inc. Diaminopropionic acid derivatives
DE60022508T2 (de) * 1999-06-14 2006-06-08 Eli Lilly And Co., Indianapolis Inhibitoren von serin proteasen
WO2001000656A2 (en) * 1999-06-29 2001-01-04 Ortho-Mcneil Pharmaceutical, Inc. Novel indazole peptidomimetics as thrombin receptor antagonists
GB0030304D0 (en) * 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030306D0 (en) * 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030303D0 (en) * 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030305D0 (en) * 2000-12-13 2001-01-24 Lilly Co Eli Compounds
US7211594B2 (en) * 2000-07-31 2007-05-01 Signal Pharmaceuticals, Llc Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
US20050009876A1 (en) * 2000-07-31 2005-01-13 Bhagwat Shripad S. Indazole compounds, compositions thereof and methods of treatment therewith
US7058826B2 (en) * 2000-09-27 2006-06-06 Amphus, Inc. System, architecture, and method for logical server and other network devices in a dynamically configurable multi-server network environment
US20020052373A1 (en) * 2000-10-26 2002-05-02 Zorn Stevin H. Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease
US6995162B2 (en) * 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
WO2003037274A2 (en) * 2001-11-01 2003-05-08 Icagen, Inc. Pyrazole-amides and-sulfonamides
JP4414881B2 (ja) * 2002-05-31 2010-02-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾール化合物およびこれを含んでなる医薬組成物
TW200500341A (en) * 2002-11-12 2005-01-01 Astrazeneca Ab Novel compounds
SE0203825D0 (sv) * 2002-12-20 2002-12-20 Astrazeneca Ab Novel fused heterocycles and uses thereof
EP1605896B1 (en) * 2003-03-12 2013-09-18 Celgene Corporation 7-amino- isoindolyl compounds amd their pharmaceutical uses
US7129264B2 (en) * 2003-04-16 2006-10-31 Bristol-Myers Squibb Company Biarylmethyl indolines and indoles as antithromboembolic agents
US20040220170A1 (en) * 2003-05-01 2004-11-04 Atkinson Robert N. Pyrazole-amides and sulfonamides as sodium channel modulators
EP1664052B1 (en) * 2003-08-15 2009-02-18 AstraZeneca AB Fused heterocycles as inhibitors of glutamate racemase (muri)
SE0302486D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
SE0302487D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
GB0504828D0 (en) * 2005-03-09 2005-04-13 Merck Sharp & Dohme Therapeutic agents
CN101141878A (zh) * 2005-03-16 2008-03-12 巴斯福股份公司 联苯-n-(4-吡啶基)甲基磺酰胺
PL1881823T3 (pl) * 2005-05-17 2015-05-29 Sarcode Bioscience Inc Kompozycje i sposoby leczenia chorób oczu
CN101258131B (zh) * 2005-09-01 2013-07-24 伊莱利利公司 作为5-HT2c受体激动剂的6-芳烷基氨基-2,3,4,5-四氢-1H-苯并[d]氮杂䓬
US20080262040A1 (en) * 2005-10-25 2008-10-23 Smithkline Beecham Corporation Chemical Compounds
AU2007233709A1 (en) * 2006-03-31 2007-10-11 Novartis Ag Organic compounds
PE20081775A1 (es) * 2006-12-20 2008-12-18 Bristol Myers Squibb Co Compuestos macrociclicos como inhibidores del factor viia
GB0716292D0 (en) * 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
CN101842359A (zh) * 2007-10-31 2010-09-22 日产化学工业株式会社 哒嗪酮化合物和p2x7受体抑制剂
US8008327B2 (en) * 2008-04-29 2011-08-30 Boehringer Ingelheim International Gmbh Indazole compounds as CCR1 receptor antagonists
CA2722811C (en) * 2008-05-06 2016-07-05 Boehringer Ingelheim International Gmbh Pyrazole compounds as ccr1 antagonists
US7879873B2 (en) * 2008-09-26 2011-02-01 Boehringer Ingelheim International Gmbh Azaindazole compounds as CCR1 receptor antagonists

Also Published As

Publication number Publication date
EA201200820A1 (ru) 2013-01-30
JP2013512954A (ja) 2013-04-18
IN2012DN05081A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html) 2015-10-09
PH12012501153A1 (en) 2012-10-22
BR112012013582A2 (pt) 2016-07-05
TW201144282A (en) 2011-12-16
IL219274A0 (en) 2012-06-28
US20110137042A1 (en) 2011-06-09
CN102596908A (zh) 2012-07-18
EP2509952A1 (en) 2012-10-17
AU2010328480A1 (en) 2012-05-17
KR20120101667A (ko) 2012-09-14
WO2011071730A1 (en) 2011-06-16
MX2012006524A (es) 2012-07-17
AR079324A1 (es) 2012-01-18
CA2782384A1 (en) 2011-06-16

Similar Documents

Publication Publication Date Title
CL2012001300A1 (es) Proceso de preparación de un compuesto de fórmula (i) en forma de sal iónica, que comprende las etapas de i) hidrogenar un compuesto de fórmula (ii) usando un catalizador metálico con hidrógeno y ii) filtrar el catalizador seguido de tratamiento con una solución ácida o gas.
CL2013003127A1 (es) Metodo para recuperar un metal a partir de un mineral que contiene metales raros, preciosos o base que comprende poner en contacto el mineral con acido, sal de cloruro y un oxidante soluble bajo condicion seleccionada para formar un residuo de mineral y una solucion de lixiviacion oxidante soluble en acido que comprende el metal.
MX2011008621A (es) Proceso para la purificacion de lipopeptidos.
EA201590751A1 (ru) Катод для электролитического выделения водорода
MY170250A (en) Mitigation of fouling in hydroformylation processes by water addition
AU2012219988A8 (en) Method for removing N2O and NOX from the nitric acid production process, and an installation suitable for same
IN2015DN01811A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
TN2013000385A1 (en) Processes for the manufacture of macrocyclic depsipeptides and new intermediates
IN2015DN01812A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
CL2012002201A1 (es) Metodo para la recuperacion de cobalto por intercambio ionico a partir del refinado que comprende: producir el refinado, el que incluye al menos cobalto, zinc, cobre, niquel y hierro ferrico, elevar el ph del refinado, remover los solidos del refinado; reducir el hierro ferrico a ferroso; cargar una unidad de intercambio ionico de recuperacion de cobre y utilizar unidad de intercambio ionico de recuperacion co/ni/zinc.
NZ700356A (en) Pyrazole compounds as sglt1 inhibitors
CO7180204A2 (es) Eliminación de hierro ferrico como hematita a presion atmosferica
EA201270237A1 (ru) Способ получения 1-бензил-3-гидроксиметил-1н-индазола и его производных и необходимые промежуточные соединения, содержащие магний
MX2011013735A (es) Procedimiento de preparacion de alquilalcanolaminas.
MY156873A (en) Novel forms of a multicyclic compound
CY1121351T1 (el) Μεθοδος για την παρασκευη οξυκωδονης
MX342570B (es) Proceso para producir granulos que comprende una o mas sales de agentes complejantes.
PE20140811A1 (es) Precipitacion de zinc de la solucion
MX2011012233A (es) Soluciones de retinoide topicas.
BR112014031919A2 (pt) processo para produção de ácido acético
IN2014DN03469A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
GB201208902D0 (en) Method and use
CO6331375A2 (es) Un proceso para la recuperacion de sulfuro metalico a partir de una solucion que contiene el ion del metal
EA201291210A1 (ru) Композиция для ухода за волосами
SA112330683B1 (ar) طريقة لإزالة أيونات فلز من محلول مائي